(See Figure 2 for a timeline of key activities associated with the GLP-1 coverage demonstrations.) Medicare coverage of GLP-1s for obesity begins in July 2026 through the Medicare GLP-1 Bridge and will be extended through the end of 2027 CMS will provide Part D beneficiaries with coverage of select GLP-1s for obesity from July 1, 2026 to December 31, 2027 (originally December 31, 2026) through the Medicare GLP-1 Bridge, which is a short-term demonstration established using Section 402 demonstration authority
What's legal and what changed
By binding to GLP-1 receptors, Ozempic promotes insulin secretion, reduces glucagon production (which lowers blood sugar), and slows down stomach emptying, leading to decreased appetite
How Meal Timing Affects Foods That Increase GLP-1 Levels Naturally How you eat is just as important as what you eat
Employer-Sponsored Plans: These plans, which cover the largest share of insured Americans, have actually been cutting GLP-1 obesity coverage due to the massive cost burden on their formularies
